MedTrace Logo

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

NCT03507543 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-03-30

No results posted yet for this study

Summary

This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.

Conditions

Interventions

DRUG

IMP4297

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Sponsors & Collaborators

  • Impact Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter · Epworth Medical Centre

  • Paul Souza · St George Private Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-03
Primary Completion
2020-09-24
Completion
2021-03-17

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03507543 on ClinicalTrials.gov